Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals announced that the USFDA inspected its Dahej manufacturing unit from 19 January 2026 to 23 January 2026. The inspection concluded with Zero observations. Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd is up for a third straight session in a row. The stock is quoting at Rs 4088, up 1.74% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 25522.15. The Sensex is at 83010.66, down 0.67%. Torrent Pharmaceuticals Ltd has added around 7.13% in last one month. Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has added around 3.29% in last one month and is currently quoting at 22217.05, down 0.2% on the day. The volume in the stock stood at 2.43 lakh shares today, compared to the daily average of 2.11 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 4087.1, up 1.65% on the day. Torrent Pharmaceuticals Ltd is up 29.19% in last one year as compared to a 9.33% gain in NIFTY and a 0.04% gain in the Nifty Pharma index.The PE of the stock is 63.73 based on TTM earnings ending September 25.Powered by Capital Market - Live

Torrent Pharma has approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) aggregating upto Rs 12,500 crore in one or more tranches on private placement basis.Powered by Capital Market - Live

Torrent Pharmaceuticals said India Ratings and Research has reaffirmed the credit rating of the company's existing banking facilities, issuer rating and non-convertible debentures at IND AA+ with a stable outlook. The rating agency has also assigned a short-term rating of IND A1+ to Torrent Pharma's proposed commercial paper programme, indicating a strong degree of safety with respect to timely servicing of financial obligations. The company's securities transfer and stakeholders relationship committee will meet on 5 January 2026 to consider the issuance of secured non-convertible debentures through a private placement, within the borrowing limits already approved by the board in July 2025. Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. On a consolidated basis, the company's net profit rose 30.46% to Rs 591 crore while net sales rose 14.66% to Rs 3246 crore in Q2 September 2025 over Q2 September 2024. Shares of Torrent Pharmaceuticals rose 0.96% to settle at Rs 3884.85 on Friday, 2 January 2026. Powered by Capital Market - Live

The proposed issuance will be within the limits already approved by the company's Board of Directors at its meeting held on 28 July 2025, the company said in an exchange filing. Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%. The counter shed 0.34% to Rs 3,807.60 on the BSE. Powered by Capital Market - Live

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 January 2026.Powered by Capital Market - Live

Torrent Pharmaceuticals announced that commercial paper of Rs 200 crore has been redeemed and repaid by the company on maturity date i.e. 23 December 2025. Powered by Capital Market - Live

Torrent Pharmaceuticals announced that NSE Sustainability Ratings and Analytics, a SEBI registered ESG Rating Provider, has independently assigned the Environmental, Social, and Governance (ESG) Rating of 70 to the Company.Powered by Capital Market - Live

Torrent Pharmaceuticals Ltd fell for a fifth straight session today. The stock is quoting at Rs 3706.6, down 0.4% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.29% on the day, quoting at 26115.75. The Sensex is at 85365.62, down 0.31%.Torrent Pharmaceuticals Ltd has gained around 2.56% in last one month.Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has increased around 0.76% in last one month and is currently quoting at 22687.55, down 0.15% on the day. The volume in the stock stood at 40074 shares today, compared to the daily average of 2.86 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 3701.7, down 0.67% on the day. Torrent Pharmaceuticals Ltd jumped 17.03% in last one year as compared to a 9.24% rally in NIFTY and a 3.15% spurt in the Nifty Pharma index.The PE of the stock is 58.96 based on TTM earnings ending September 25.Powered by Capital Market - Live

On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25, supported by double-digit growth across major geographies. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%. Operating EBITDA increased 15% YoY to Rs 1,083 crore, with the margin steady at 33%. Profit after tax (PAT) surged 30% YoY to Rs 591 crore, translating to a net margin of 18% compared with 16% in the year-ago quarter. R&D spend for the quarter stood at Rs 156 crore, up 8% year-on-year, accounting for 5% of revenues. The company reported an exceptional item of Rs 13 crore, related to regulatory and statutory filing fees for acquiring a controlling stake in J.B. Chemicals & Pharmaceuticals. On the geography front, India revenues grew 12% YoY to Rs 1,820 crore, outperforming the Indian Pharmaceutical Market (IPM) growth of 8%, led by strong traction in chronic therapies and successful new launches. Torrent's chronic segment grew 13% vs IPM's 11%, and 21 of its brands now feature among the top 500 in India. Brazil business rose 21% YoY to Rs 318 crore, driven by strong brand performance and new product launches, while U.S. revenues surged 26% YoY to Rs 337 crore on the back of recent launches that achieved targeted market share. Germany revenues grew 5% to Rs 303 crore, although supply disruptions at a third-party supplier affected constant currency growth, which declined 5% YoY. Torrent Pharma is the flagship Company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved. Powered by Capital Market - Live